ST Germain D J Co. Inc. Has $9.60 Million Stock Position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

ST Germain D J Co. Inc. cut its holdings in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 5.1% during the 4th quarter, HoldingsChannel.com reports. The fund owned 90,845 shares of the medical equipment provider’s stock after selling 4,885 shares during the period. ST Germain D J Co. Inc.’s holdings in Zimmer Biomet were worth $9,596,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. BLB&B Advisors LLC grew its position in shares of Zimmer Biomet by 2.1% in the 3rd quarter. BLB&B Advisors LLC now owns 4,900 shares of the medical equipment provider’s stock valued at $529,000 after purchasing an additional 100 shares during the period. FWG Holdings LLC boosted its holdings in shares of Zimmer Biomet by 2.9% in the third quarter. FWG Holdings LLC now owns 3,591 shares of the medical equipment provider’s stock valued at $372,000 after buying an additional 101 shares during the period. Financial Advocates Investment Management increased its position in shares of Zimmer Biomet by 3.5% during the third quarter. Financial Advocates Investment Management now owns 3,053 shares of the medical equipment provider’s stock worth $330,000 after acquiring an additional 103 shares in the last quarter. M&R Capital Management Inc. raised its holdings in shares of Zimmer Biomet by 14.1% during the third quarter. M&R Capital Management Inc. now owns 852 shares of the medical equipment provider’s stock worth $92,000 after acquiring an additional 105 shares during the period. Finally, Mill Creek Capital Advisors LLC lifted its position in Zimmer Biomet by 5.1% in the 2nd quarter. Mill Creek Capital Advisors LLC now owns 2,195 shares of the medical equipment provider’s stock valued at $238,000 after acquiring an additional 106 shares in the last quarter. 88.89% of the stock is owned by institutional investors and hedge funds.

Zimmer Biomet Stock Performance

Shares of ZBH stock traded up $2.11 during trading on Friday, reaching $103.65. 866,367 shares of the company’s stock were exchanged, compared to its average volume of 1,456,078. The firm’s fifty day moving average price is $108.09 and its 200-day moving average price is $108.05. Zimmer Biomet Holdings, Inc. has a twelve month low of $100.67 and a twelve month high of $133.90. The stock has a market capitalization of $20.63 billion, a PE ratio of 19.71, a PEG ratio of 1.96 and a beta of 1.02. The company has a quick ratio of 0.70, a current ratio of 1.36 and a debt-to-equity ratio of 0.38.

Zimmer Biomet (NYSE:ZBH) last issued its quarterly earnings data on Wednesday, October 30th. The medical equipment provider reported $1.74 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $1.74. The company had revenue of $1.82 billion during the quarter, compared to analysts’ expectations of $1.80 billion. Zimmer Biomet had a return on equity of 12.95% and a net margin of 14.27%. The business’s revenue was up 4.1% on a year-over-year basis. During the same quarter in the previous year, the company posted $1.65 earnings per share. As a group, sell-side analysts anticipate that Zimmer Biomet Holdings, Inc. will post 7.99 EPS for the current year.

Zimmer Biomet Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, January 31st. Shareholders of record on Monday, December 30th will be given a dividend of $0.24 per share. The ex-dividend date of this dividend is Monday, December 30th. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.93%. Zimmer Biomet’s payout ratio is presently 18.25%.

Analyst Ratings Changes

A number of equities analysts have issued reports on ZBH shares. Barclays lowered their target price on Zimmer Biomet from $125.00 to $118.00 and set an “underweight” rating for the company in a report on Thursday, December 12th. Evercore ISI dropped their target price on Zimmer Biomet from $113.00 to $110.00 and set an “in-line” rating on the stock in a research report on Tuesday, October 1st. Oppenheimer reduced their price target on Zimmer Biomet from $145.00 to $135.00 and set an “outperform” rating for the company in a research report on Tuesday, October 15th. Needham & Company LLC reiterated a “hold” rating on shares of Zimmer Biomet in a report on Thursday, October 31st. Finally, Raymond James reduced their target price on shares of Zimmer Biomet from $128.00 to $123.00 and set an “outperform” rating for the company in a report on Monday, October 14th. Two research analysts have rated the stock with a sell rating, eleven have given a hold rating and eight have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $123.33.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.